Promising undervalued biotech companies offer an excellent opportunity for significant future returns. Waiting until the sector is back in the spotlight often results in a missed opportunity. As share prices will have risen by then.
Several of the Aescap portfolio companies in both the Aescap Life Sciences and Aescap Genetics fund have an internal team with hundreds of AI experts. Is this just a hype or is there a real added value? And what are they aiming for?
Artificial Intelligence (AI) in Biotech: Revolutionizing Medicine Development
UCB is a biopharma company with over 8 600 employees, headquartered in Brussels, Belgium The company develops and manufactures multiple medicines, sold in 40 countries. In this company showcase we describe why we think UCB is an interesting biopharmaceutical growth story, even after 95 years of existence.
UCB: An interesting biopharmaceutical growth story
Upward potential of portfolio further increased. The fund made a small positive net performance for the third quarter of 1,8%. Continuous poor market sentiment continued to depress share prices of our portfolio companies despite the present and expected future revenue and profit growth these innovative companies face.